Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis: The COVER Randomized Clinical Trial. (PubMed, JAMA Intern Med) - Oct 6, 2026 - P4 | "Patients had received a primary messenger RNA COVID-19 vaccine series and were receiving stable immunomodulatory therapy with anti-tumor necrosis factor, anti-interleukin-17, abatacept, and a Janus kinase inhibitor (JAKi)...Routine interruption of these therapies at the time of COVID-19 dose administration is likely not warranted. ClinicalTrials.gov Identifier: NCT05080218."
Clinical • Journal • Ankylosing Spondylitis • Axial Spondyloarthritis • Immunology • Infectious Disease • Inflammatory Arthritis • Novel Coronavirus Disease • Oncology • Psoriatic Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A • TNFA
|
|
Amy S Mudano; Gary Cutter; Geoffrey M Thiele; Jayashree Sinha; Jeffrey R Curtis; John Tesser; Kelly Y Chun; Kevin L Winthrop; Mark Law; Michael D George; Michael Zikry; Monique Bastidas; Naiara Alvarez; Sandeep K Sodhi; Ted R Mikuls
|